Obsidian Therapeutics (NASDAQ:OBX) Rating Lowered to Sell at Wall Street Zen

Obsidian Therapeutics (NASDAQ:OBX) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday, Wall Street Zen reports.

A number of other research firms have also weighed in on OBX. Zacks Research raised Obsidian Therapeutics to a “hold” rating in a research note on Thursday, August 6th. TD Cowen assumed coverage on Obsidian Therapeutics in a research report on Thursday, August 6th. They set a “buy” rating for the company. Weiss Ratings assumed coverage on Obsidian Therapeutics in a research report on Wednesday, September 2nd. They set a “sell (d-)” rating for the company. Leerink Partners started coverage on Obsidian Therapeutics in a research note on Tuesday, September 22nd. They set an “outperform” rating and a $32.00 target price on the stock. Finally, Piper Sandler started coverage on Obsidian Therapeutics in a research note on Wednesday, August 5th. They set an “overweight” rating and a $42.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $39.00.

Obsidian Therapeutics Price Performance

Shares of OBX stock opened at $11.77 on Friday. The business has a fifty day simple moving average of $17.05. Obsidian Therapeutics has a 52-week low of $11.61 and a 52-week high of $49.97.

About Obsidian Therapeutics

Obsidian Therapeutics is a biotechnology company focused on developing engineered cell and gene therapies for serious diseases. Its research centers on technologies designed to control the activity, timing and location of therapeutic proteins within engineered cells.

The company’s CytoDRiVE platform is intended to enable small-molecule regulation of protein expression, which may help improve the safety and effectiveness of cell therapies. Obsidian has applied this technology to immune-cell therapies, including programs designed to support the treatment of solid tumors, as well as to other therapeutic protein and gene-modulation applications.

Obsidian Therapeutics is based in the United States and has operated as a privately held biotechnology company, according to available company information.